Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Diseases and Illnesses
  5. Covid 19

Covid-19

Thumbnail
February 28, 2023

Go or no go? Vaccines and neurology up for discussion

FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.

Thumbnail
January 31, 2023

Pfizer faces the Covid trough

Thumbnail
February 28, 2023

Go or no go? Vaccines and neurology up for discussion

FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.

Thumbnail
January 31, 2023

Pfizer faces the Covid trough

Article image
Vantage logo
October 13, 2022

Few safe havens surface in another down quarter for biopharma

Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.

Article image
Vantage logo
September 01, 2022

US FDA approval tracker: August 2022

Article image
Vantage logo
August 26, 2022

With Covid pandemic over, Moderna heads to the courts

Article image
Vantage logo
August 11, 2022

Valneva throws in the Covid towel

Article image
Vantage logo
July 15, 2022

No end to the Novavax deflation

Article image
Vantage logo
July 13, 2022

Few biopharma risers stand out at the half year

A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.

Article image
Vantage logo
July 13, 2022

Humanigen is left nursing Covid losses

Article image
Vantage logo
July 04, 2022

US FDA approval tracker: June 2022

Article image
Vantage logo
June 27, 2022

Covid vaccine development could go Omicron-and-on

Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?

  • Load More
Article image
Vantage logo
October 13, 2022

Few safe havens surface in another down quarter for biopharma

Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.

Article image
Vantage logo
September 01, 2022

US FDA approval tracker: August 2022

Article image
Vantage logo
August 26, 2022

With Covid pandemic over, Moderna heads to the courts

Article image
Vantage logo
August 11, 2022

Valneva throws in the Covid towel

Article image
Vantage logo
July 15, 2022

No end to the Novavax deflation

Article image
Vantage logo
July 13, 2022

Few biopharma risers stand out at the half year

A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.

Article image
Vantage logo
July 13, 2022

Humanigen is left nursing Covid losses

Article image
Vantage logo
July 04, 2022

US FDA approval tracker: June 2022

Article image
Vantage logo
June 27, 2022

Covid vaccine development could go Omicron-and-on

Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up